Check 35,000+ stocks against 26 valuation models and 37 quality factors

All Cosmos Bio-Tech Holding Corp (4148) fair value: what the stock is really worth

As of Sep 24, 2026: fair value of All Cosmos Bio-Tech Holding Corp TWD 32.88, price TWD 32.40, upside +1.5%, quality 55 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? Yes
Good quality? Yes
Add to watchlist

Basic Materials · TW · ISIN KYG0232P1072

AC Some data Sep 24, 2026

All Cosmos Bio-Tech Holding Corp

4148 · TW

NeutralThe stock looks roughly fairly valued with average quality.

·Fair value 32.88 TWD · Fairly valued (+1%)

!Quality 55/100

!Weak Growth (revenue 5y +12.4 %/yr)

!Thin margins · 5.0% net margin (TTM)

✓Low debt · generates free cash flow

·3.09% dividend yield

✓Ranks above peers (10/14)

!Narrow moat 31/100

!Evidence only medium, so the estimate is less certain

!Weak on past: 24 out of 100

26 models, one by oneBear 24.66 TWD to bull 41.11 TWD Growth analysisrevenue history, year by year Quality 55/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch All Cosmos Bio-Tech Holding Corp for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range 29.45 TWD – 88.22 TWD · fair‑value band 24.66 TWD – 41.11 TWD · the 32.40 TWD price screens below the 32.88 TWD fair value. Dashed = 300-day average. As of Sep 24, 2026.

Follow All Cosmos Bio-Tech Holding in your weekly email

Every Wednesday you see whether All Cosmos Bio-Tech Holding is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

All Cosmos Bio-Tech Holding Corporation, through its subsidiaries, manufactures and sells bio-organic and bio-chemical compound fertilizers in Malaysia and internationally. The company offers bio-chemical fertilizers, as well as offers water reutilization services. It also engages in the research and development of microorganisms for waste disposal of oil-palm; and wholesale of probiotics. In addition, the company offers compound fertilizer; manufactures and sells biological vaccines; and sale of health care, food, cosmetic, skin care, and pharmaceutical products. All Cosmos Bio-Tech Holding Corporation was founded in 1999 and is headquartered in Pasir Gudang, Malaysia.

Stock analysis

All Cosmos Bio-Tech Holding Corp (4148) currently trades at 32.40 TWD, while our model-based Fair Value estimate is 32.88 TWD, implying the stock looks roughly 1.5% fairly valued today.

Valuation

Bull case: the DCF Models group reads highest at a median of 55.62 TWD per share, and 20 of the 26 models we run sit above the 32.40 TWD price.

Bear case: the Dividend Discount group reads lowest at 4.85 TWD, and 6 of the 26 models stay below the price. Evidence for this calculation is medium.

Scenario range: 24.66 TWD (bear) to 41.11 TWD (bull), the price of 32.40 TWD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 55/100 (solid quality), in the Basic Materials sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

All Cosmos Bio-Tech Holding Corp reported revenue of 2.9B TWD in FY2025 versus 2.2B TWD in FY2021, a compound +7.6%/yr. Reported net income was 153M TWD in FY2025, compounding −6.3%/yr from FY2021.

Key figures

Market cap 2.9B TWD (≈ $92.0M) · P/E ratio 14.3 · P/S ratio 0.74 · EPS (TTM) 2.27 TWD · Dividend yield 3.1% · Net margin 5.2% · Return on equity 6.0% · Return on assets (EBIT) 8.2%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).

What moves the price

The share trades about 26% below its 52-week high and 10% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Basic Materials peers we cover trades at 10% fair-value upside, at 1%, 4148 screens richer than that median.

Fair Value models

Bear 24.66 TWD Fair Value 32.88 TWD Bull 41.11 TWD

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (0.9325 TWD per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

FCF DCF 43.02 TWD 52.78 TWD 64.73 TWD 82

Growth DCF 43.13 TWD 51.64 TWD 61.46 TWD 80

Owner Earnings 39.01 TWD 47.30 TWD 57.45 TWD 78

All 26 models by family

DCF Models

FCF DCF 43.02 TWD 52.78 TWD 64.73 TWD 82

Owner Earnings 39.01 TWD 47.30 TWD 57.45 TWD 78

5Y Revenue Exit 49.23 TWD 68.30 TWD 92.37 TWD 73

5Y EBITDA Exit 47.96 TWD 65.97 TWD 86.58 TWD 76

5Y P/E Exit 42.35 TWD 55.62 TWD 69.20 TWD 72

10Y Revenue Exit 45.18 TWD 60.12 TWD 79.63 TWD 68

10Y EBITDA Exit 45.38 TWD 58.75 TWD 75.91 TWD 70

10Y P/E Exit 42.33 TWD 52.65 TWD 64.73 TWD 65

Earnings-Based

Graham-Dodd 15.47 TWD 45.12 TWD 59.61 TWD 65

Lynch FV 9.38 TWD 13.40 TWD 17.42 TWD 61

PEG = 1.0 9.38 TWD 13.40 TWD 17.42 TWD 57

EPV 38.18 TWD 40.80 TWD 42.92 TWD 74

Dividend Discount

Gordon GGM 3.32 TWD 5.56 TWD 7.21 TWD 68

DDM Multi-Stage 3.32 TWD 4.85 TWD 5.98 TWD 67

Multiples

P/E Multiple 29.01 TWD 38.68 TWD 48.36 TWD 63

P/S Multiple 29.01 TWD 38.68 TWD 48.36 TWD 58

P/B Multiple 29.01 TWD 38.68 TWD 48.36 TWD 55

EV/EBIT 62.67 TWD 78.11 TWD 93.55 TWD 66

EV/EBITDA 56.79 TWD 70.27 TWD 83.76 TWD 67

EV/Revenue 56.49 TWD 73.70 TWD 90.90 TWD 54

Asset-Based

NCAV (Graham) 20.40 TWD 27.33 TWD 40.80 TWD 54

Growth DCF

Growth DCF 43.13 TWD 51.64 TWD 61.46 TWD 80

Rev-Margin DCF 49.23 TWD 68.38 TWD 89.96 TWD 73

Economic Profit

Residual Income 28.44 TWD 27.77 TWD 23.89 TWD 76

ROIC Compounder 38.18 TWD 40.80 TWD 44.20 TWD 72

Growth Earnings

Growth-Adj P/E 24.00 TWD 34.29 TWD 44.58 TWD 67

Open the full fair value analysis →

Notify me when 4148 reaches fair value

Put 4148 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 55/100

Of which business quality 58 · Market factors (momentum, volatility) 40

Profitability 36

Margins and returns on capital today

Quality Growth 61

Are margins and returns improving?

Cashflow 59

Earnings quality: real cash, not paper profit

Fin. Strength 98

Balance sheet, leverage, solvency risk

Investment 90

Disciplined investing over empire-building

Low Volatility 82

Calm price path (market factor)

Momentum 26

Price trend over the last 3–12 months (market factor)

52W Momentum 15

Distance to the 52-week high (market factor)

Net Issuance 0

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 40/100

Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Revenue growth 1 year

+19.9%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

−7.3%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+12.4%

Start year 2020 (pandemic). Over 10 years: +2.7% a year

Revenue growth 15 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+10.6%

’14

’15

’16

’17

’18

’19

’20

’21

’22

’23

’24

’25

What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.

+8.8%

Earnings growth per share plus dividend.

Earnings per share, growth per year+5.7%

Dividend (yield on the price)3.1%

Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.6% vs −8%, picking up

Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.9% → 10%

Start year 2020 (pandemic)

Growth Forecast

Little optimism in the price

The price assumes less growth than the company has delivered so far.

What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).

+1.7%

Yearly growth needed for the next five years to justify today's price.

What forecasts expect

n/a

No analyst forecast available.

After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about +0.1% a year for the price.

Watch 4148, get fair value alerts →

Compare All Cosmos Bio-Tech Holding Corp with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Agricultural Inputs · 180 stocks

Beats the industry median on 10/14 measures

Overall it ranks above its industry peers.

Valuation

Quality Score 55 · Above median

Fair Value upside +2% · Above median

Profitability

Return on equity (TTM) 6% · Below median

Return on assets 4% · Above median

Net margin (TTM) 5% · Above median

Operating margin (TTM) 5% · Below median

Growth and dividend

Revenue growth −4% · Bottom 25%

Dividend yield (TTM) 3.1% · Above median

Balance sheet

Debt / equity 0.05× · Below median

Valuation Multiplesvs Agricultural Inputs median · lower = cheaper

P/E (TTM) 14.3× · Cheaper than median

P/B 1.07× · Cheaper than median

P/S (TTM) 1.00× · Pricier than median

P/FCF 0.4× · Cheaper than median

EV/EBITDA 5.4× · Cheaper than median

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)35 · sector 21

FUTURE (revenue growth)0 · sector 36

PAST (return on equity)24 · sector 24

HEALTH (low debt)98 · sector 97

DIVIDEND (yield)62 · sector 41

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Agricultural Inputs stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Corteva, Inc CTVA	$80.34	$28.49	−65%
Nutrien Ltd NTR	$75.13	$82.61	+10%
Qinghai Salt Lake Industry Co 000792	¥24.87	¥27.36	+10%
CF Industries Holdings CF	$120.64	$161.00	+33%
SABIC Agri-Nutrients Company 2020	124.00 SAR	150.65 SAR	+21%
Yara International ASA YAR	kr 446.70	kr 659.87	+48%
Yunnan Yuntianhua Co 600096	¥27.95	¥50.49	+81%
The Mosaic Company MOS	$24.73	$25.77	+4%
Asia-potash International Investment (Guangzhou)Co.,Ltd., 000893	¥39.75	¥38.01	−4%
ICL Group ICL	$5.40	$2.98	−45%

Explore undervalued stocks

More undervalued Basic Materials stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

All Cosmos Bio-Tech Holding Corp · Fair Value
32.88 TWD +1%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/4148" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">All Cosmos Bio-Tech Holding Corp · Fair Value</span><br><b style="font-size:20px">32.88 TWD</b> <span style="color:var(--fvc-g-mitte);font-weight:700;font-size:14px">+1%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "All Cosmos Bio-Tech Holding Corp Fair Value". https://www.fairvalue-calculator.com/stock/4148

Frequently asked questions

Is All Cosmos Bio-Tech Holding Corp (4148) overvalued or undervalued?

As of Sep 24, 2026, our model estimates a fair value of 32.88 TWD versus a price of 32.40 TWD, about +1% upside (fairly valued).

What is the fair value of 4148?

Our model-based fair value for All Cosmos Bio-Tech Holding Corp is 32.88 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 32.40 TWD.

What is the quality score of 4148?

All Cosmos Bio-Tech Holding Corp has a Quality Score of 55/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for All Cosmos Bio-Tech Holding Corp (4148)?

Our model-based price target is the fair value of 32.88 TWD (as of Sep 24, 2026) from 26 valuation models. Cautious scenario 24.66 TWD, optimistic scenario 41.11 TWD. It is a calculation from audited fundamentals, not an analyst target.

What is the All Cosmos Bio-Tech Holding Corp stock forecast for 2026?

Our models put fair value at 32.88 TWD, about +1% upside versus a price of 32.40 TWD (fairly valued). Cautious scenario 24.66 TWD, optimistic scenario 41.11 TWD. The calculation is refreshed regularly with new filings.

What is the revenue of All Cosmos Bio-Tech Holding Corp (4148)?

All Cosmos Bio-Tech Holding Corp reported trailing-twelve-month revenue of about 2.9B TWD (latest available figure, as of Sep 24, 2026).

Does All Cosmos Bio-Tech Holding Corp pay a dividend?

All Cosmos Bio-Tech Holding Corp currently shows a dividend yield of about 3.09% relative to its recent price (as of Sep 24, 2026).

What growth is priced into All Cosmos Bio-Tech Holding Corp (4148)?

For today's price to be fair in a discounted-cash-flow model, All Cosmos Bio-Tech Holding Corp would have to grow free cash flow by +1.7 % per year for five years (discount rate 13.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +12.4 % per year. As of Sep 24, 2026.

What discount rate (WACC) does the fair value of 4148 use?

Our models discount All Cosmos Bio-Tech Holding Corp at 13.3 %: a base by market capitalisation (micro), country premium for Taiwan. The same rate applies in all 26 models.

What is a reverse DCF?

A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For All Cosmos Bio-Tech Holding Corp that is +1.7 % per year a year over ten years, using the same discount rate (13.3 %) and the same formula as our fair value.

How much growth has All Cosmos Bio-Tech Holding Corp (4148) delivered so far?

Over the past 5 years revenue at All Cosmos Bio-Tech Holding Corp grew +12.4 % a year. The price currently implies +1.7 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.

How fast is the sector of All Cosmos Bio-Tech Holding Corp (4148) growing?

The median revenue growth in the sector is +3.3 % a year. That is the yardstick for the growth priced into All Cosmos Bio-Tech Holding Corp (+1.7 % per year a year): it shows whether the expectation is within the usual range or beyond it.

What is the free cash flow yield of All Cosmos Bio-Tech Holding Corp (4148)?

The free-cash-flow yield on the price is 7.13 %: that much free cash flow All Cosmos Bio-Tech Holding Corp produces per unit of market value. When it exceeds the discount rate of our models (13.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.

What is the intrinsic value of All Cosmos Bio-Tech Holding Corp (4148)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For All Cosmos Bio-Tech Holding Corp it is 32.88 TWD per share (as of Sep 24, 2026), against a price of 32.40 TWD. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).

Is All Cosmos Bio-Tech Holding Corp stock overvalued or undervalued in 2026?

As of Sep 24, 2026, 4148 trades below its calculated fair value: price 32.40 TWD, fair value 32.88 TWD, a gap of about +1% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of 4148?

No. The price is what the market pays today (32.40 TWD); the fair value is what the company's own numbers justify (32.88 TWD). For All Cosmos Bio-Tech Holding Corp the two are 0.4780 TWD per share apart. That gap is exactly why we show both numbers side by side.

How much is All Cosmos Bio-Tech Holding Corp worth?

The market values All Cosmos Bio-Tech Holding Corp at about 2.9B TWD (market capitalisation, as of Sep 24, 2026). Per share that is 32.40 TWD; our models calculate a fair value of 32.88 TWD per share.

What do the bullish and bearish scenarios say about 4148?

Our models span a range for All Cosmos Bio-Tech Holding Corp: cautious scenario 24.66 TWD, base 32.88 TWD, optimistic 41.11 TWD per share (as of Sep 24, 2026, price 32.40 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the P/E ratio of 4148?

All Cosmos Bio-Tech Holding Corp trades at a price-to-earnings ratio of 14.3 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 32.88 TWD is built from several models across several years. Other multiples: P/B 1.1, P/S 1.0, EV/EBITDA 5.4.

How solid is the balance sheet of All Cosmos Bio-Tech Holding Corp (4148)?

Balance-sheet figures for All Cosmos Bio-Tech Holding Corp (as of Sep 24, 2026): return on equity 6.0%, debt of 0.05 per unit of equity. They feed the Quality Score of 55/100, which measures business quality independently of the share price.

How far is 4148 from its 52-week high?

All Cosmos Bio-Tech Holding Corp trades at 32.40 TWD, about 26% below its 52-week high of 43.60 TWD and 10% above the low of 29.45 TWD (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 32.88 TWD is for.

Which stocks are comparable to All Cosmos Bio-Tech Holding Corp?

From the same area (Basic Materials) we also value Corteva, Inc, Nutrien Ltd, Qinghai Salt Lake Industry Co, CF Industries Holdings, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is All Cosmos Bio-Tech Holding Corp stock attractive at the current price?

The data as of Sep 24, 2026: price 32.40 TWD, calculated fair value 32.88 TWD (+1%), Quality Score 55/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of 4148 calculated?

We run All Cosmos Bio-Tech Holding Corp through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 32.88 TWD, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 13.0 % above its aggregate fair value. All Cosmos Bio-Tech Holding Corp currently trades 1 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of All Cosmos Bio-Tech Holding Corp (4148)?

The closing price on Sep 24, 2026 was 32.40 TWD. Our model-based fair value is 32.88 TWD, about +1% upside (fairly valued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with All Cosmos Bio-Tech Holding Corp right now?

The price sits close to our fair value, market and models broadly agree here, little valuation tension. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Where does the earnings growth of All Cosmos Bio-Tech Holding Corp (4148) come from?

Earnings per share at All Cosmos Bio-Tech Holding Corp grew −7.7 % a year from 2014 to 2025. Broken into its drivers: revenue per share −0.9 %, EBIT margin −5.1 %, tax rate −4.0 %, residual (interest, one-offs) +2.2 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of All Cosmos Bio-Tech Holding Corp

How large is the market capitalisation of All Cosmos Bio-Tech Holding Corp (4148)?

The market capitalisation of All Cosmos Bio-Tech Holding Corp is 2.9B TWD (≈ $92.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of All Cosmos Bio-Tech Holding Corp (4148)?

The price-to-sales ratio of All Cosmos Bio-Tech Holding Corp is 0.74 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of All Cosmos Bio-Tech Holding Corp (4148)?

Earnings per share at All Cosmos Bio-Tech Holding Corp are 2.27 TWD (price ÷ EPS = P/E 14.3). Earnings per share over the last twelve months: total profit spread across every single share.

What is the dividend yield of All Cosmos Bio-Tech Holding Corp (4148)?

The dividend yield of All Cosmos Bio-Tech Holding Corp is 3.1% (payout 44.1%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.

What is the net margin of All Cosmos Bio-Tech Holding Corp (4148)?

The net margin of All Cosmos Bio-Tech Holding Corp is 5.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of All Cosmos Bio-Tech Holding Corp (4148)?

The return on equity (ROE) of All Cosmos Bio-Tech Holding Corp is 6.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of All Cosmos Bio-Tech Holding Corp (4148)?

On an EBIT basis the return on assets of All Cosmos Bio-Tech Holding Corp is 8.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of All Cosmos Bio-Tech Holding Corp (4148)?

The operating margin of All Cosmos Bio-Tech Holding Corp is 5.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at All Cosmos Bio-Tech Holding Corp (4148)?

Revenue at All Cosmos Bio-Tech Holding Corp is growing −3.7% versus a year earlier (3y avg −7.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at All Cosmos Bio-Tech Holding Corp (4148)?

Earnings per share at All Cosmos Bio-Tech Holding Corp are growing −59.2% versus a year earlier. How much earnings per share grew versus a year earlier.

How much net cash does All Cosmos Bio-Tech Holding Corp (4148) hold?

All Cosmos Bio-Tech Holding Corp holds more cash than debt, 843M TWD net (fiscal year 2025). The company holds more cash than debt, a safety cushion.

Free · no account needed

Watch All Cosmos Bio-Tech Holding Corp in the live analysis

One click puts All Cosmos Bio-Tech Holding Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.